Earnings are set to sink at Burberry Group plc, Hikma Pharmaceuticals plc and J Sainsbury plc! Should you buy?

Royston Wild runs the rule over FTSE 100 (INDEXFTSE: UKX) strugglers Burberry Group plc (LON: BRBY), Hikma Pharmaceuticals plc (LON: HIK) and J Sainsbury plc (LON: SBRY).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m considering the investment potential of three FTSE 100 (INDEXFTSE: UKX) laggards.

Catwalk colossus

Wavering emerging market growth is weighing heavily on the luxury goods market, a trend that’s playing havoc with Burberry (LSE: BRBY) in particular. The fashion and classics brand saw earnings tank 10% in the year to March 2016, and a further 4% slide is expected by City analysts in the current period.

This comes as little surprise — Burberry advised last month that, since the start of the present fiscal year, “the external environment has remained challenging and underlying cost inflation pressures persist.”

It’s difficult to say just when Burberry’s bottom line will tick higher again, such is the extent of sales pressure in key markets such as Hong Kong. But I remain convinced that the enduring allure of Burberry’s brand — combined with huge investment in its online operations — should blast earnings higher in the longer term.

And I reckon a forward P/E rating of 16.3 times is a decent level at which to latch onto this promising growth story.

Medical marvel

Medicines giant Hikma Pharmaceuticals (LSE: HIK) has also been a major earnings casualty in recent times.

The result of sinking demand for its Generics products — combined with the impact of colossal R&D costs — pushed Hikma’s bottom line 5% lower in 2015. And an extra 15% decline is predicted for the current year.

However, I reckon Hikma’s improving product pipeline should deliver brilliant earnings expansion in the longer term, particularly as the $2.65bn takeover of US giant Roxane Laboratories pays off. On top of this, Hikma’s focus on the fast-growing markets of Africa and the Middle East should copper-bottom stunning revenues growth, in my opinion.

A forward P/E rating of 25.4 times may be heady at first glance. But I expect this to topple in the coming years as drugs demand takes off.

Shopper struggles

I’m not so convinced by the growth outlook over at Sainsbury’s (LSE: SBRY) as fragmentation in the British grocery sector intensifies.

The London chain has seen earnings sink during the past two years as the likes of Aldi and Lidl have really got into gear. And a further drop — this time by a chunky 9% — is expected in the period to March 2017.

And I can’t see a reason to expect Sainsbury’s to flip back into the black any time soon.

Sure, the business may be chucking vast sums at product and brand development, and has enjoyed great success with premium labels like Taste The Difference. And Sainsbury’s is hoping the takeover of Argos will light a fire under its online proposition.

But the multi-year expansion schemes of its upmarket and discount rivals, both on the street and in cyberspace, mean that revenues at Sainsbury’s are likely to remain under significant strain for the foreseeable future.

A prospective P/E rating of 11.2 times may be cheap on paper. But not cheap enough to make me take a punt, I’m afraid.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Burberry and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Would Warren Buffett buy BP shares, as oil excitement grows?

Warren Buffett is a big investor in the oil business, and BP's performance has been attracting investor attention in results…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Here’s how long-term loyalty to UK shares can lead to dazzling returns!

The most successful UK and US share investors buy shares to hold for the long term, as this report shows.

Read more »

Investing Articles

NatWest has just smashed brokers’ dividend forecasts!

After NatWest delivered a Valentine’s Day surprise to investors, our writer thinks the experts may have to raise their dividend…

Read more »

Investing Articles

The NatWest share price slips in early trading despite positive FY 2024 results. What’s the deal?

The NatWest share price is down slightly this morning after the bank released its final results for 2024. Our writer…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

My Legal & General shares have climbed just 7% — so how come I’m sitting on a 20% gain?

Harvey Jones' trading account is showing only a modest return on his Legal & General Shares, but on drilling down…

Read more »

Investing Articles

Prediction: the BP share price could rise in 2025 (or it might fall!)

Following this week’s release of the energy giant’s 2024 results, our writer reviews the prospects for the BP (LSE:BP.) share…

Read more »

many happy international football fans watching tv
Investing Articles

What’s gone wrong with the FTSE 100’s ‘King of Trainers’?

Feeling the pain of a 28% drop in the JD Sports share price over the past three months, our writer…

Read more »

Investing Articles

Is it too late for investors to consider buying these outstanding FTSE 100 shares?

Stephen Wright wonders whether now's the time to consider buying shares in the FTSE 100’s outstanding companies, despite some high…

Read more »